Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease

Published:2022-04-25 Issue:11 Volume:55 Page:1389-1401
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Bergqvist Viktoria¹²,Holmgren Johanna¹²,Klintman Daniel¹²,Marsal Jan¹²³^ORCID

Affiliation:

1. Department of Gastroenterology Skane University Hospital Lund/Malmö Sweden

2. Section of Medicine Department of Clinical Sciences, Lund University Lund Sweden

3. Section of Immunology Department of Experimental Medical Science, Lund University Lund Sweden

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16927

Reference48 articles.

1. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases

2. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab

3. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease

4. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

5. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease;European Journal of Gastroenterology & Hepatology;2024-07-08

2. Valoración de la transición de vedolizumab intravenoso a subcutáneo en pacientes con enfermedad inflamatoria intestinal;Gastroenterología y Hepatología;2024-05

3. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease;Digestive Diseases and Sciences;2024-04-18

4. Letter to the Editor: Switching from vedolizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study;Digestive and Liver Disease;2024-04

5. Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge;Journal of Clinical Medicine;2024-02-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3